[WePp0305] The HEPADOSE Study: Evaluation of protease inhibitors and non nucleoside analogue plasma concentrations in HIV/HCV and HIV infected patients

3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Rio de Janeiro - July 24 - 27, 2005

THE HEPADOSE STUDY: EVALUATION OF PROTEASE INHIBITORS AND NON NUCLEOSIDE ANALOGUE PLASMA CONCENTRATIONS IN HIV/HCV AND HIV INFECTED PATIENTS

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePp0305

Dominguez S.¹, Peytavin G.², Guiguet M.¹, Calvez V.¹, Costagliola D.¹, Bricaire F.¹, Poynard T.¹, Katlama C.¹, Benhamou Y.¹
¹Pitie salpetriere hospital,INSERM unity U720,University Pierre and Marie Curie, PARIS, France, ²Bichat Claude Bernard hospital, PARIS, France

INTRODUCTION: Whether HIV/HCV coinfection could impair drug metabolism remains unclear.

METHODS: To compare plasma ARV concentrations in a cross sectionnal study we performed plasma ARV concentrations (C_min) in HIV/HCV pts with a documented liver biopsy within two years matched on HIV pts according to sex and ARV. We used the standard threshold value to define the NNRTI and PI expected therapeutic concentrations . Statistical analysis was performed by using non parametric Wilcoxon test, or Fisher's exact test.

RESULTS: We enrolled 73 HIV/HCV and 66 HIV monoinfected pts, HIV RNA was <200 cps/mL in 68% and 83% pts ,median CD4 cell count was 331 and 385/mm³ respectively. Median PI C_min were similar in the two groups, except for LPV wich was lower in HIV-HCV pts (p=0.04). Both EFV and NVP C_min were higher in HIV/HCV pts compared to HIV pts Moreover, according to the fibrosis stage NNRTI C_min were significantly over the expected therapeutic concentration in HIV/HCV pts: 86% in F4 stage , 56% in F0-F3 stage compared to 24% in HIV pts (p=0.01). Among pts with NNRTI C_min over the expected therapeutic concentration cytolysis _ grade 2 was significantly more frequent in HIV/HCV pts compared to HIV pts (39% vs 10% p=0.02).

ARV C_min normal value(ng/ml)	VIH (n=66) n, Median C_min ,range	VIH/VHC (n=73)n, Median C_min ,range
Lopinavir (3000-7000)	[n=14] 5990 (4114-7920)	[n=16] 3673 (2535-4992) p=0.04
Ritonavir (400-1000)	[n=39] 373 (202-667)	n=47] 314 (161-646) p=0.62
Efavirenz (1100-3000)	[n=8] 1494 (1362-3083)	[n=12] 3583 (3270-4339) p=0.04
Nevirapine (3400-6000)	[n=13] 3954 (3461-4942)	[n=11] 5331 (3990-7326) p=0.12

CONCLUSIONS: In HIV/HCV patients C_min did not change significantly for PI except for lopinavir, but NNRTI were strongly overdosed in HIV-HCV pts suggesting the need of drug monitoring in this population.

Download PDF of this abstract.

050724
Clinical | WePp0305 | Stephanie Dominguez
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.